206 related articles for article (PubMed ID: 29487712)
21. BCL6 inhibition ameliorates resistance to ruxolitinib in
Tsuzuki S; Yasuda T; Goto H; Maeda N; Akahane K; Inukai T; Yamamoto H; Karnan S; Ota A; Hyodo T; Konishi H; Hosokawa Y; Kiyoi H; Hayakawa F
Haematologica; 2023 Feb; 108(2):394-408. PubMed ID: 36005560
[TBL] [Abstract][Full Text] [Related]
22. SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.
Sarno J; Savino AM; Buracchi C; Palmi C; Pinto S; Bugarin C; Jager A; Bresolin S; Barber RC; Silvestri D; Israeli S; Dyer MJS; Cazzaniga G; Nolan GP; Biondi A; Davis KL; Gaipa G
Oncotarget; 2018 May; 9(33):22872-22885. PubMed ID: 29796158
[TBL] [Abstract][Full Text] [Related]
23. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract][Full Text] [Related]
24. A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.
Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB
Int J Biol Macromol; 2021 Nov; 190():214-223. PubMed ID: 34481852
[TBL] [Abstract][Full Text] [Related]
25.
Steeghs EMP; Jerchel IS; de Goffau-Nobel W; Hoogkamer AQ; Boer JM; Boeree A; van de Ven C; Koudijs MJ; Besselink NJM; de Groot-Kruseman HA; Zwaan CM; Horstmann MA; Pieters R; den Boer ML
Oncotarget; 2017 Oct; 8(52):89923-89938. PubMed ID: 29163799
[No Abstract] [Full Text] [Related]
26. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
27. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
28. Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells.
Al-Rawashde FA; Al-Wajeeh AS; Vishkaei MN; Saad HKM; Johan MF; Taib WRW; Ismail I; Al-Jamal HAN
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145344
[TBL] [Abstract][Full Text] [Related]
29. An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia.
Mohamed SMA; Schofield P; McCalmont H; Moles E; Friedrich KH; Kavallaris M; Christ D; Bayat N; Lock RB
Int J Biol Macromol; 2024 Jan; 254(Pt 1):127596. PubMed ID: 37898250
[TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
31. Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.
Downes CEJ; McClure BJ; Bruning JB; Page E; Breen J; Rehn J; Yeung DT; White DL
NPJ Precis Oncol; 2021 Aug; 5(1):75. PubMed ID: 34376782
[TBL] [Abstract][Full Text] [Related]
32. Identification of
Zhang XY; Dai HP; Li Z; Yin J; Lang XP; Yang CX; Xiao S; Zhu MQ; Liu DD; Liu H; Shen HJ; Wu DP; Tang XW
Front Oncol; 2020; 10():611467. PubMed ID: 33505919
[TBL] [Abstract][Full Text] [Related]
33. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
34. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
35. Why and how to treat Ph-like ALL?
Roberts KG
Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia.
Dou H; Chen X; Huang Y; Su Y; Lu L; Yu J; Yin Y; Bao L
Genes Chromosomes Cancer; 2017 Feb; 56(2):135-146. PubMed ID: 27637012
[TBL] [Abstract][Full Text] [Related]
37. mTOR inhibition enhances efficacy of dasatinib in
Gotesman M; Vo TT; Herzog LO; Tea T; Mallya S; Tasian SK; Konopleva M; Fruman DA
Oncotarget; 2018 Jan; 9(5):6562-6571. PubMed ID: 29464092
[TBL] [Abstract][Full Text] [Related]
38. Gene Expression Profiling and Protein Analysis Reveal Suppression of the C-Myc Oncogene and Inhibition JAK/STAT and PI3K/AKT/mTOR Signaling by Thymoquinone in Acute Myeloid Leukemia Cells.
Almajali B; Johan MF; Al-Wajeeh AS; Wan Taib WR; Ismail I; Alhawamdeh M; Al-Tawarah NM; Ibrahim WN; Al-Rawashde FA; Al-Jamal HAN
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337104
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia.
Lee BJ; Mallya S; Dinglasan N; Fung A; Nguyen T; Herzog LO; Thao J; Lorenzana EG; Wildes D; Singh M; Smith JAM; Fruman DA
Front Oncol; 2021; 11():673213. PubMed ID: 34408976
[TBL] [Abstract][Full Text] [Related]
40. Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.
Chen JA; Hou Y; Roskin KM; Arber DA; Bangs CD; Baughn LB; Cherry AM; Ewalt MD; Fire AZ; Fresard L; Kearney HM; Montgomery SB; Ohgami RS; Pearce KE; Pitel BA; Merker JD; Gotlib J
Blood Adv; 2021 Sep; 5(17):3492-3496. PubMed ID: 34505882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
